CA
NZ
UK
AU
IND
US
…
aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. Its lead therapeutic candidate efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; Phase 2 clinical trial to treat Sarcoidosis and systemic sclerosis- interstitial lung disease (ILDs); and treatment of other ILDs, such as chronic hypersensitivity pneumonitis (CHP) and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase, which is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
aTyr Pharma is a clinical-stage biotechnology company developing novel protein therapeutics focused on inflammatory and fibrotic lung disorders, with its lead candidate advancing through clinical development for serious pulmonary indications. Long-term growth may be supported by successful clinical and regulatory progress, expansion into related respiratory diseases, and strategic partnerships that could help commercialize its pipeline and broaden addressable markets. Investors may find the company attractive for its differentiated therapeutic approach addressing unmet needs in respiratory disease.
Material risks include high clinical and regulatory risk, absence of marketed products, the likely need for additional financing, and significant competition from larger biopharma firms.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -74.12M | -64.02M | -50.40M | -45.34M | -33.78M |
| Minority interest | 0.01M | -0.00M | 0.01M | 0.01M | 0.01M |
| Net income | -74.12M | -64.02M | -50.39M | -45.34M | -33.77M |
| Selling general administrative | 17.60M | 13.78M | 12.98M | 13.98M | 10.75M |
| Selling and marketing expenses | - | - | 2.74M | 1.70M | 1.30M |
| Gross profit | -1.36M | 0.23M | -2.39M | 8.69M | -1.30M |
| Reconciled depreciation | 1.55M | 1.54M | 2.74M | 1.70M | 1.30M |
| Ebit | -77.63M | -67.91M | -54.92M | -46.40M | -33.78M |
| Ebitda | -76.07M | -66.37M | -52.18M | -44.71M | -32.47M |
| Depreciation and amortization | 1.55M | 1.54M | 2.74M | 1.70M | 1.30M |
| Operating income | -77.63M | -67.91M | -54.92M | -46.40M | -34.02M |
| Other operating expenses | 77.82M | 68.15M | 55.27M | 56.79M | 34.02M |
| Income tax expense | - | - | -0.01M | -0.01M | -0.01M |
| Total revenue | 0.19M | 0.23M | 0.35M | 10.39M | 0.00M |
| Total operating expenses | 76.26M | 68.15M | 55.27M | 55.09M | 32.71M |
| Cost of revenue | 1.55M | 1.54M | 2.74M | 1.70M | 1.30M |
| Total other income expense net | 3.51M | 3.89M | 4.52M | 1.06M | 0.24M |
| Net income from continuing ops | -74.12M | -64.02M | -50.40M | -45.34M | -33.78M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 94.16M | 96.83M | 120.65M | 95.79M | 115.54M |
| Other current assets | 0.68M | 8.09M | 2.39M | 2.95M | 5.22M |
| Total liab | 26.88M | 27.00M | 30.18M | 24.50M | 6.41M |
| Total stockholder equity | 67.48M | 70.02M | 90.66M | 71.46M | 109.30M |
| Other current liab | 9.79M | 9.39M | 11.56M | 9.86M | 4.00M |
| Common stock | 0.10M | 0.08M | 0.06M | 0.03M | 0.03M |
| Capital stock | 0.10M | 0.08M | 0.06M | 0.03M | 0.03M |
| Retained earnings | -606.16M | -532.05M | -468.02M | -417.63M | -372.30M |
| Other assets | - | - | 0.00M | - | - |
| Cash | 10.74M | 11.05M | 22.54M | 9.98M | 2.34M |
| Total current liabilities | 15.15M | 14.97M | 16.42M | 13.86M | 6.01M |
| Current deferred revenue | - | - | - | - | 0.00M |
| Net debt | 1.29M | 2.23M | -7.45M | 1.55M | -0.96M |
| Short term debt | 1.47M | 1.25M | 1.33M | 0.89M | 0.98M |
| Short long term debt total | 12.03M | 13.28M | 15.10M | 11.53M | 1.38M |
| Other stockholder equity | 673.55M | 602.02M | 558.69M | 489.50M | 481.83M |
| Total current assets | 80.24M | 81.95M | 102.99M | 80.87M | 113.57M |
| Short term investments | 67.94M | 61.07M | 75.62M | 56.16M | 105.58M |
| Net receivables | 0.87M | 1.74M | 2.44M | 11.78M | 0.43M |
| Accounts payable | 3.89M | 4.32M | 3.53M | 3.11M | 1.03M |
| Accumulated other comprehensive income | -0.01M | -0.04M | -0.07M | -0.43M | -0.26M |
| Non currrent assets other | 1.31M | 3.02M | 0.13M | 0.19M | 0.16M |
| Non current assets total | 13.93M | 14.88M | 17.66M | 14.91M | 1.97M |
| Capital lease obligations | 12.03M | 13.28M | 15.10M | 11.53M | 1.38M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | -4.99M | 17.23M | -20.13M | 47.24M | -91.57M |
| Total cashflows from investing activities | -5.05M | 17.23M | - | - | - |
| Net borrowings | -0.54M | -0.50M | - | - | - |
| Total cash from financing activities | 66.01M | 39.86M | 66.23M | 5.45M | 110.03M |
| Net income | -74.12M | -64.02M | -50.39M | -45.34M | -33.77M |
| Change in cash | -1.03M | -12.02M | 12.88M | 7.64M | -14.62M |
| Begin period cash flow | 14.01M | 26.03M | 13.15M | 2.34M | 16.95M |
| End period cash flow | 12.98M | 14.01M | 26.03M | 9.98M | 2.34M |
| Total cash from operating activities | -61.99M | -69.12M | -33.22M | -41.89M | -33.08M |
| Issuance of capital stock | 66.42M | 40.26M | 66.52M | 5.47M | 109.95M |
| Depreciation | 1.55M | 1.54M | 2.74M | 1.70M | 1.30M |
| Other cashflows from investing activities | 1.85M | 0.01M | - | - | - |
| Change to account receivables | 0.86M | 0.40M | 9.05M | -11.92M | 1.60M |
| Other cashflows from financing activities | - | 0.10M | 0.10M | 0.04M | 0.07M |
| Capital expenditures | 0.08M | 0.07M | 4.21M | 1.64M | 0.19M |
| Change in working capital | 7.45M | -6.92M | 15.01M | -0.83M | -2.59M |
| Stock based compensation | 5.00M | 2.99M | 2.60M | 2.15M | 1.61M |
| Other non cash items | -1.87M | -2.71M | -3.18M | 11.16M | 2.93M |
| Free cash flow | -62.06M | -69.18M | -37.44M | -43.53M | -33.27M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| ATYR aTyr Pharma, Inc. |
-0.43 8.01% |
4.94 | - | - | 424.97 | 1.24 | 89.03 | -0.81 |
| NVO Novo Nordisk A/S |
0.86 2.20% |
40.00 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
18.88 3.50% |
558.88 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
109.12 13.33% |
927.89 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. Its lead therapeutic candidate efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; Phase 2 clinical trial to treat Sarcoidosis and systemic sclerosis- interstitial lung disease (ILDs); and treatment of other ILDs, such as chronic hypersensitivity pneumonitis (CHP) and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase, which is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.
10240 Sorrento Valley Road, San Diego, CA, United States, 92121
858 731 8389
58
| Name | Title | Year Born |
|---|---|---|
| Dr. Sanjay S. Shukla M.D., M.S. | President, CEO & Director | 1972 |
| Ms. Jill M. Broadfoot CPA | Chief Financial Officer | 1962 |
| Ms. Nancy E. Denyes Krueger J.D. | General Counsel & Corporate Secretary | 1968 |
| Xiang-Lei Yang Ph.D. | Founder | NA |
| Dr. Jayant Aphale MBA, Ph.D. | Vice President of Technical Operations | 1960 |
| Ms. Ashlee Dunston | Director of Investor Relations & Corporate Communications | NA |
| Mr. Peter Villiger | Vice President of Corporate Development | NA |
| Ms. Danielle Campbell | VP of Human Resource | NA |
| Dr. Leslie Nangle Ph.D. | Vice President of Research | NA |
| Dr. Ying J. Buechler Ph.D. | Executive Director of Biologics Development & Manufacturing | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-1.82%
Communication Services
-0.22%
Consumer Cyclical
-0.13%
Consumer Defensive
+0.32%
Energy
+0.15%
Financial Services
-0.85%
Financials
+2.34%
Healthcare
-1.28%
Industrials
-0.96%
Real Estate
-0.38%
Technology
-2.73%
Utilities
-0.31%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...